Coya Therapeutics, Inc. (COYA) Completes 137-Patient ALS Trial Enrollment
Coya Therapeutics completed enrollment for its 137-patient ALS trial, ALSTARS, with topline data expected in early Q2 2027. The company reported a Q3 net loss of $10.6M and $35.8M in cash as of September 30, 2026, expected to fund operations into H2 2027. According to Coya, the next major catalyst is the trial readout.
How this was made
The 30-second read
Why it matters
The enrollment completion removes a near-term execution risk, but the disclosed loss and cash balance raise questions about financing until the Q2 2027 readout.
Market read
Provides a fresh data point for traders tracking biotech trial milestones; limited immediate price impact but sets the stage for future moves.
What to watch
Potential dilution from future financing needs and competition from other ALS therapies could dampen upside.
Background
Coya Therapeutics is a clinical-stage biotech focused on ALS therapies. The ALSTARS trial is its lead program.
Ticker impact
Coya Therapeutics reported completion of enrollment for its ALSTARS ALS trial (137 patients) and disclosed a Q3 net loss of $10.6M with $35.8M cash.
likely modest pressure as investors price in the loss, with upside potential ahead of the Q2 2027 readout.
First report of trial enrollment; loss numbers are new and may trigger short-term sell, but future data could reverse sentiment.
Market effects
Highlights ongoing activity in the ALS biotech space, may prompt peers to be watched for similar trial milestones.
Limited to US biotech investors; no broader regional effect.
Minor, confined to specialty biotech sector.
Counterpoint
The enrollment news may be overhyped; the sizable loss and cash runway could signal funding risk before the readout.
Key entities
- companyCoya Therapeutics, Inc.
Biotech company developing ALS treatments.
